| pubmed-article:18640575 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C0013018 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C0003442 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C0445356 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:18640575 | lifeskim:mentions | umls-concept:C1708943 | lld:lifeskim |
| pubmed-article:18640575 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:18640575 | pubmed:dateCreated | 2008-7-21 | lld:pubmed |
| pubmed-article:18640575 | pubmed:abstractText | Antithymocyte globulin (ATG) as part of conditioning regimens is known to reduce the incidence and severity of acute and chronic graft-versus-host disease (aGVHD, cGVHD). The influence of ATG on transplant-related mortality (TRM) and disease-free survival (DFS) is controversial, and may depend on the dose and timing of ATG. We retrospectively compared 2 doses of ATG-Fresenius (ATG-F) in patients undergoing matched unrelated donor allogeneic hematopoetic stem cell transplantation (HSCT) for hematologic malignancies. A dose of 60 mg/kg body weight has previously been recommended for ATG-F. All patients received cyclosporine A and short course methotrexate. ATG-F was administered at a dose of 30 mg/kg on day -1 (ATG-30 group, n = 34) or 20 mg/kg/day on days -3 to -1 (ATG-60 group, n = 49). There was no difference in time to leukocyte and platelet engraftment in the 2 groups. The incidence of aGVHD grade II-IV (50% versus 53%, P = .83) and grade III-IV (27 versus 20%, P = .60) was similar in the ATG-30 versus ATG-60 groups, respectively. There was a trend to a higher incidence of cGVHD in the ATG-30 group (59% versus 40%, P = .14). The estimated 3-year incidence of relapse was similar in the ATG-30 and ATG-60 groups (15% versus 16%, P = .84) whereas the 2-year TRM was lower for the ATG-30 group (12% versus 33%, P = 0.02), mainly because of a higher incidence of fatal infections in the ATG-60 group. This resulted in a better DFS (73% versus 51%, P = .07) for the ATG-30 group. ATG-F (30 mg/kg) administered as a single dose on day -1 may lead to better outcome in patients undergoing unrelated donor allogeneic HSCT compared to 60 mg/kg given in 3 equivalent doses. A prospective randomized study comparing these 2 doses of ATG-F is warranted. | lld:pubmed |
| pubmed-article:18640575 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18640575 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18640575 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18640575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18640575 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18640575 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18640575 | pubmed:issn | 1523-6536 | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:KrögerNicolau... | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:ZabelinaTatja... | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:ZanderAxel... | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:ErttmannRudol... | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:FehseBorisB | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:AyukFrancisF | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:BacherUlrikeU | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:WolschkeChris... | lld:pubmed |
| pubmed-article:18640575 | pubmed:author | pubmed-author:DiyachenkoGal... | lld:pubmed |
| pubmed-article:18640575 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18640575 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18640575 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18640575 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18640575 | pubmed:pagination | 913-9 | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:meshHeading | pubmed-meshheading:18640575... | lld:pubmed |
| pubmed-article:18640575 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18640575 | pubmed:articleTitle | Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. | lld:pubmed |
| pubmed-article:18640575 | pubmed:affiliation | Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany. ayuketan@uke.uni-hamburg.de | lld:pubmed |
| pubmed-article:18640575 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18640575 | pubmed:publicationType | Comparative Study | lld:pubmed |
